Heilind Electronics Introduces Brady M410 and M510 Series Printers
Heilind Electronics Introduces Brady M410 and M510 Series Printers
September 09, 2024 11:48 ET | Heilind Electronics
WILMINGTON, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Heilind Electronics, a global leader in electronics distribution, announces Brady’s new line of M410 and M510 label printers. The M410 series...
Heilind Electronics Features Molex UltraWize Wire-to-Board High-Current Connectors & Cable Assemblies
Heilind Electronics Features Molex UltraWize Wire-to-Board High-Current Connectors & Cable Assemblies
August 12, 2024 09:45 ET | Heilind Electronics
WILMINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Heilind Electronics, a leading global distributor of electronic components and authorized distributor for Molex, is now stocking Molex UltraWize...
Heilind Electronics Featuring Hirose DF60FS Series Wire-to-Board Connectors
Heilind Electronics Featuring Hirose DF60FS Series Wire-to-Board Connectors
June 27, 2024 10:30 ET | Heilind Electronics
WILMINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Heilind Electronics, a leading global distributor of interconnect, electromechanical, and sensor products, features the Hirose DF60FS Series...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024 01:00 ET | Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024 01:00 ET | Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...
Celebrate the Bold, Colorful Characters of Brooklyn
THE BROOKLYN ROASTING COMPANY INTRODUCES TWO SUPER-PREMIUM COFFEE BLENDS TO THE KEURIG® K-CUP® POD SYSTEM
April 10, 2024 10:00 ET | The Brooklyn Roasting Company
Brooklyn, NY, April 10, 2024 (GLOBE NEWSWIRE) -- The Brooklyn Roasting Company, New York's best-loved local roasting company, today announced a new partnership with Keurig Dr Pepper (KDP) with the...
Nerdio logo large.jpg
Nerdio Unveils Major Upgrades in Nerdio Manager for Enterprise and Nerdio Manager for MSP, Enhancing Both Platforms
April 02, 2024 09:00 ET | Nerdio
CHICAGO, April 02, 2024 (GLOBE NEWSWIRE) -- Nerdio, a premier solution for organizations of all sizes looking to manage and cost-optimize native Microsoft cloud technologies, today announced...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024 13:24 ET | Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024 01:00 ET | Sandoz Group
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
January 31, 2024 01:00 ET | Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE             Tyruko® approved for all indications of reference medicine             Tyruko® biosimilar to treat...